May 27, 2020Press releases
- Novartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms
- Novartis presents five-year analysis showing long-term data of targeted therapy in patients with high-risk, Stage III BRAF+ melanoma following surgery
- Novartis announces a subgroup analysis of overall survival results for our CDK4/6 inhibitor to be presented at ASCO20 Virtual Scientific Program
Now is the time to accelerate progress in cancer care
COVID-19 is having a huge impact on cancer care. Susanne Schaffert, President of Novartis Oncology, reflects on the current situation and looks at what can be done in this LinkedIn article.
